ArticleClinical case reports2026
Intracardiac Metastasis From a Testicular Yolk Sac Tumor With Brain and Pulmonary Involvement: A Multimodality Management Case Report.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac metastasis from non-seminomatous germ cell tumors (NSGCTs) is exceedingly rare and represents an aggressive disease course. We report a 37-year-old man with a testicular yolk sac tumor who initially declined adjuvant therapy after orchiectomy. He later developed pulmonary metastases treated with BEP chemotherapy, followed by progressive disease with brain involvement requiring emergent decompressive craniectomy and whole-brain radiotherapy. Salvage TIP chemotherapy was administered. Persistent pulmonary disease led to thoracotomy, during which a discrete metastatic deposit in the right atrium was identified and surgically resected. Histopathology confirmed metastatic yolk sac tumor in all sites. The patient subsequently received maintenance therapy with oxaliplatin and bevacizumab. Follow-up has been based on clinical assessment and serial tumor marker monitoring, demonstrating ongoing biochemical and clinical stability for approximately 6 months following initiation of maintenance therapy, with the patient remaining on treatment at the time of this report. This case highlights the unpredictable metastatic behavior of NSGCTs and underscores the importance of multidisciplinary management in achieving disease control in rare and life-threatening metastatic presentations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.